| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LGALS13 |
| Uniprot No | Q9UHV8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-139aa |
| 氨基酸序列 | MSSLPVPYKL PVSLSVGSCV IIKGTPIHSF INDPQLQVDF YTDMDEDSDI AFRFRVHFGN HVVMNRREFG IWMLEETTDY VPFEDGKQFE LCIYVHYNEY EIKVNGIRIY GFVHRIPPSF VKMVQVSRDI SLTSVCVCN |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LGALS13(胎盘galectin-13.PP13)重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"Galectin-13/PP13: A Member of the Placental Galectin Family Implicated in Maternal Adaptation to Pregnancy"*
**作者**: Meiri H. et al.
**摘要**: 研究探讨了重组LGALS13蛋白在妊娠早期胎盘发育中的作用，发现其通过调节母体免疫耐受和血管生成，促进胚胎着床及妊娠维持，可能作为子痫前期的潜在生物标志物。
---
2. **文献名称**: *"Structural and Functional Characterization of Recombinant Human Galectin-13"*
**作者**: Than N.G. et al.
**摘要**: 通过重组表达纯化LGALS13蛋白并解析其晶体结构，揭示了其独特的糖结合特性及与胎盘细胞表面配体的相互作用，为研究其在妊娠相关疾病中的分子机制提供结构基础。
---
3. **文献名称**: *"PP13 as a Placental Immunomodulator: Recombinant Protein Therapy in a Mouse Model of Preterm Birth"*
**作者**: Balogh A. et al.
**摘要**: 在小鼠模型中验证了重组LGALS13蛋白的免疫调节功能，证明其可通过抑制炎症因子释放延缓早产进程，提示其在妊娠并发症治疗中的潜在应用价值。
---
(注：以上文献信息为示例性内容，实际文献需通过PubMed等数据库检索确认。)
LGALS13. also known as galectin-13 or placental protein 13 (PP13), is a member of the galectin family of β-galactoside-binding proteins. It is primarily expressed in the placenta, specifically in syncytiotrophoblasts, and plays a critical role in pregnancy-related processes. Galectin-13 is implicated in maternal immune tolerance, placental development, and vascular remodeling during gestation. Structurally, it contains a conserved carbohydrate recognition domain (CRD) that mediates interactions with glycoproteins or glycolipids, influencing cell adhesion, signaling, and apoptosis.
Recombinant LGALS13 protein is produced using biotechnological systems (e.g., bacterial or mammalian expression) to study its biological functions. Research highlights its involvement in pregnancy disorders, particularly preeclampsia, where reduced expression or mutations in LGALS13 are linked to impaired placental implantation and spiral artery remodeling. This association has driven interest in recombinant LGALS13 as a potential diagnostic biomarker or therapeutic target for pregnancy complications.
Additionally, galectin-13 exhibits immunomodulatory properties, such as inducing apoptosis of activated T cells and promoting anti-inflammatory responses, which may help maintain fetal-maternal tolerance. Its recombinant form enables mechanistic studies, including ligand-binding assays, structural analyses, and functional experiments in cellular or animal models. Beyond obstetrics, emerging studies explore its roles in cancer and immune regulation, though these areas remain less characterized.
Overall, recombinant LGALS13 serves as a vital tool for deciphering galectin-mediated pathways in reproduction and disease, with translational potential in maternal-fetal medicine and immunology.
×
